Charles River Laboratories International (NYSE:CRL) Stock Price Up 11.3% – Here’s Why

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) were up 11.3% during trading on Thursday . The company traded as high as $183.66 and last traded at $183.0280. Approximately 675,337 shares were traded during trading, a decline of 28% from the average daily volume of 942,033 shares. The stock had previously closed at $164.49.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks Research increased its FY2026 EPS estimate for Charles River Laboratories International to $10.91 from $10.79, implying slightly better near-term earnings power.
• Positive Sentiment: The firm also lifted FY2027 EPS forecasts to $12.11 from $11.62 and raised several quarterly estimates, including Q2 2027, Q3 2027, Q4 2027, and Q1 2028, reinforcing a more optimistic longer-term outlook.
• Positive Sentiment: Zacks Research raised Q2 2026, Q3 2026, and Q4 2026 earnings estimates as well, suggesting momentum may be improving across the next several reporting periods.
• Neutral Sentiment: Brokerage sentiment remains constructive overall, with the stock previously noted as having a consensus “Moderate Buy” rating.
• Neutral Sentiment: Recent market commentary also pointed to a 5% share-price surge earlier this week, adding to already positive trading momentum.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. UBS Group raised their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Finally, Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Stock Down 0.2%

The business has a 50-day moving average price of $169.08 and a 200-day moving average price of $181.20. The company has a market capitalization of $8.72 billion, a price-to-earnings ratio of -48.15, a price-to-earnings-growth ratio of 2.07 and a beta of 1.44. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the company posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its stake in Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in Charles River Laboratories International during the fourth quarter valued at $176,478,000. Victory Capital Management Inc. lifted its stake in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after acquiring an additional 575,039 shares in the last quarter. Finally, National Bank of Canada FI boosted its position in Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.